SynAct Investor Relations Material
Latest events
Q3 2023
SynAct
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
SynAct Pharma AB, develops medicines for acute deterioration in inflammatory diseases. The company's lead product, Synacto®, is a mix of three anti-inflammatory protease inhibitors for the treatment of patients who have recently had a heart attack, have re-opened their old heart wounds due to surgery, or are going to undergo procedures in which blood clotting is needed. SynAct Pharma AB is based in Lund, Sweden.
Key slides for SynAct
Latest articles
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
Ticker symbol
SYNACT
Country
🇸🇪 Sweden